» Articles » PMID: 8642857

Expression of PKC Isozyme and MDR-associated Genes in Primary and Relapsed State AML

Overview
Journal Leukemia
Specialties Hematology
Oncology
Date 1996 Mar 1
PMID 8642857
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

For investigation of relative differences in mRNA expression levels and of correlations in the expression of genes possibly involved in multidrug resistance (MDR) of acute myelogenous leukemias (AML), a complementary DNA polymerase chain reaction (cDNA-PCR) analysis was established for the genes encoding MDR1/P-glycoprotein, the multidrug resistance-associated protein (MRP), topoisomerase II alpha, topoisomerase II beta, topoisomerase I, glutathione S-transferase pi, protein kinase C (PKC) isozymes alpha, beta 1, beta 2, epsilon, eta, theta and cyclin A. In a first descriptive study comprising samples of childhood or adult AML we calculated the mean values from primary (n=14) or relapsed (n=23) states of the diseases, respectively. We found in the latter significant increases of MDR1, MRP, gst pi, and PKC theta gene expression. MDR1 and MRP gene expression levels were generally correlated (rs= +0.4128, P<0.02, n=37), as well as topoisomerase II alpha and cyclin A gene expression levels (rs= +0.8727, P<0.0001, n=35). Within the group of relapsed state AML a significant negative correlation between the gene expression levels of MDR1 and topoisomerase II alpha (rs= -0.5500, P<0.01, n=22) was observed. Remarkably, highly significant positive correlations were found for MDR1/PKC eta (rs= +0.5560, P<0.001, n=32), MRP/PKC theta (rs= +0.6573, P<0.0001, n=34) and MRP/PKC eta (rs= +0.5241, P<0.005, n=32).

Citing Articles

Association between Dysfunction of the Nucleolar Stress Response and Multidrug Resistance in Pediatric Acute Lymphoblastic Leukemia.

Nakagawa S, Kawahara K, Okamoto Y, Kodama Y, Nishikawa T, Kawano Y Cancers (Basel). 2022; 14(20).

PMID: 36291909 PMC: 9601175. DOI: 10.3390/cancers14205127.


Protein Kinase C Epsilon Overexpression Is Associated With Poor Patient Outcomes in AML and Promotes Daunorubicin Resistance Through p-Glycoprotein-Mediated Drug Efflux.

Nicholson R, Menezes A, Azevedo A, Leckenby A, Davies S, Seedhouse C Front Oncol. 2022; 12:840046.

PMID: 35707351 PMC: 9191576. DOI: 10.3389/fonc.2022.840046.


A Pilot Phase II Study of the Feasibility and Efficacy of Vincristine Sulfate Liposome Injection in Patients With Relapsed or Refractory Acute Myeloid Leukemia.

Seegars M, Woods R, Ellis L, Bhave R, Howard D, Manuel M J Hematol. 2021; 10(1):1-7.

PMID: 33643502 PMC: 7891907. DOI: 10.14740/jh771.


The Novel Phospholipid Mimetic KPC34 Is Highly Active Against Acute Myeloid Leukemia with Activated Protein Kinase C.

Alexander P, Kucera G, Pladna K, Pardee T Transl Oncol. 2020; 13(7):100780.

PMID: 32428837 PMC: 7232109. DOI: 10.1016/j.tranon.2020.100780.


Sequential adaptive changes in a c-Myc-driven model of hepatocellular carcinoma.

Dolezal J, Wang H, Kulkarni S, Jackson L, Lu J, Ranganathan S J Biol Chem. 2017; 292(24):10068-10086.

PMID: 28432125 PMC: 5473214. DOI: 10.1074/jbc.M117.782052.